Safety and efficacy of intracoronary tirofiban administration in patients with serious thrombus burden and ST-elevation myocardial infarction undergoing percutaneous coronary intervention

OBJECTIVE: This work aims to explore the safety and efficacy of intracoronary tirofiban administration in patients with serious thrombus burden and ST-elevation myocardial infarction (STEMI) undergoing emergency percutaneous coronary intervention (PCI). PATIENTS AND METHODS: A total of 104 patients with serious thrombus burden and acute STEMI were randomly divided into treatment (intracoronary tirofiban administration, 56 cases) and control (48 cases) groups. Comparison of coronary blood flow, ST-segment resolution (STR), duration of hospital stay, 30-day major adverse cardiac events (MACE) and complications such as hemorrhage was conducted. RESULTS: In treatment group, the percentage of thrombolysis in myocardial infarction-3 (TIMI-3) flow in the infarct-related artery (IRA) increased (89.3% to 85.4, p < 0.05), blood flow in the IRA calculated with TIMI frame count method enhanced [(1.68 +/- 0.23) ml/s to (1.42 +/- 0.31) ml/s, p < 0.05], STR on electrocardiogram (ECG) enlarged [(64.3 +/- 7.84)% to (48.6 +/- 6.47)%, p < 0.05)] and the prevalence of MACE decreased (10.7% to 18.8%, p < 0.05), all of which were significantly different from those of control group, but no statistical difference in complications was observed between two groups (p > 0.05). CONCLUSIONS: It was simple, safe and effective to perform intracoronary tirofiban administration in patients with serious thrombus burden and STEMI when undergoing emergency PCI.